Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Pro, Barbara; Advani, Ranjana H.; Brice, Pauline; Bartlett, Nancy L.; Rosenblatt, J. D.; Illidge, T.; Matous, J.; Ramchandren, Rod; Fanale, Michelle A.; Connors, Joseph M.; Yang, Yinmo; Sievers, Eric L.; Kennedy, Dallas C.; Shustov, Andrei R.

doi:10.1200/jco.2011.29.15_suppl.8032

Cited by 19 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A subsequent Phase III study (AETHERA) in HL patients at risk for relapse after ASCT showed a median progression-free survival (PFS) of 42.9 months when BV was used as consolidation therapy versus 24.1 months in the placebo group [11]. In a Phase II study, BV also showed significant activity in relapsed or refractory systemic anaplastic large cell lymphoma, with an ORR of 86% and a CR in 53% of patients [12]. In these studies, the most commonly reported side effect was peripheral neuropathy which affected 36–56% of patients treated with BV.…”

Section: Introductionmentioning

confidence: 99%

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Delacruz

Setlik

Hassantoufighi

et al. 2016

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD). The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response. This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens. Both regimens appear effective and have manageable toxicities. Further clinical trials assessing novel BV combinations are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Delacruz

Setlik

Hassantoufighi

et al. 2016

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

show abstract

“…During the 52nd Annual Meeting of the American Society of Hematology (December, 2010), results from a Phase II trial showed complete remission in 17 out of 30 ALCL patients and partial remission in nine others, for an objective response rate by investigator assessment of 87% [16]. An update of results from this study was given at the ASCO meeting in June, 2011 [17], confirming the encouraging performance and the moderate toxicity observed with this drug. Seattle Genetics (http://www.seagen.com/index.php) has announced in a press release that the US FDA accepted two Biologics License Applications (BLAs) for bretuximab vedotin, one for the treatment of relapsed or refractory ALCL patients, and the other for treatment of patients with Hodgkin lymphoma, in which the drug has also shown clinical benefit.…”

Section: Improvement Of Direct Toxicity To Cancer Cellsmentioning

confidence: 69%

Novel Antibody-Based Proteins for Cancer Immunotherapy

Fuenmayor

Montano

2011

Cancers

View full text Add to dashboard Cite

The relative success of monoclonal antibodies in cancer immunotherapy and the vast manipulation potential of recombinant antibody technology have encouraged the development of novel antibody-based antitumor proteins. Many insightful reagents have been produced, mainly guided by studies on the mechanisms of action associated with complete and durable remissions, results from experimental animal models, and our current knowledge of the human immune system. Strikingly, only a small percent of these new reagents has demonstrated clinical value. Tumor burden, immune evasion, physiological resemblance, and cell plasticity are among the challenges that cancer therapy faces, and a number of antibody-based proteins are already available to deal with many of them. Some of these novel reagents have been shown to specifically increase apoptosis/cell death of tumor cells, recruit and activate immune effectors, and reveal synergistic effects not previously envisioned. In this review, we look into different approaches that have been followed during the past few years to produce these biologics and analyze their relative success, mainly in terms of their clinical performance. The use of antibody-based antitumor proteins, in combination with standard or novel therapies, is showing significant improvements in objective responses, suggesting that these reagents will become important components of the antineoplastic protocols of the future.

show abstract

“…They reported manageable adverse events and objective responses in 75% of the patients. In a phase II, single-arm, multicenter trial that studied Brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma, the authors reported objective responses in 86% of the patients and high proportion of complete responses (Pro et al, 2011). Finally, the most common significantly reported adverse reactions were rash, nausea, diarrhea, neutropenia, anemia and thrombocytopenia (Younes et al, 2010;Chen et al, 2011;Pro et al, 2011; Adcetris prescribing information, September 2013)…”

Section: Pharmacokineticsmentioning

confidence: 99%

Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines

et al. 2015

View full text Add to dashboard Cite

Targeted drug delivery is a method of delivering bioactive compounds to a patient in a manner that increases the therapeutic index. The main goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. Antibody-drug conjugates (ADC) represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies with the potent cell killing activity of cytotoxic bioactive compounds. ADCs are complex molecules composed of an antibody linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug. The key components of ADC include a monoclonal antibody, a stable linker and a cytotoxic agent to target a variety of cancers. The present mini-review deals with the examination of clinical use and pharmacological properties, as well as the safety of antibody-drug conjugates that are marketed. Ado-trastuzumab emtasine and brenduximab vedotin were examined regarding their mechanism of action, pharmacology, clinical use and safety. These ADCs selectively deliver cargoes to tumor cells and provide clinical benefit by minimizing systemic toxicity.

show abstract

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Cited by 19 publications

References 0 publications

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Novel Antibody-Based Proteins for Cancer Immunotherapy

Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines

Contact Info

Product

Resources

About